Genelux Corporation
$3.00
+1.0%Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -3.5).
Valuation inputs: P/E -3.5, earnings yield N/A, momentum +1.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -2.8%, ROIC -2.5%).
Profitability stack: net margin -4018.1%, ROE -2.8%, ROIC -2.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +39.3%, momentum +1.0%, net margin -4018.1%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Genelux Corporation Market vs Earnings Trajectory
Loading price and EPS data...
Genelux Corporation Fair Value Envelope
Genelux Corporation Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Genelux Corporation Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Genelux Corporation Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Genelux Corporation Street Expectations Map
Wall Street analysts project that GNLX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 17.33, with estimates ranging from a low of 16.00 to a high of 20.00.
The consensus 1-year price target stands at 17.33, with estimates ranging from a low of 16.00 to a high of 20.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Genelux Corporation Insider Positioning
During the last 12 months, insiders have purchased $3.29M and sold $7.21M worth of GNLX shares, resulting in $3.91M of net selling activity.
3 Months
0
0.00
20.3K
56.91K
-57K
-$57K
3-6 Months
0
0.00
10.0K
28.96K
-29K
-$29K
6-9 Months
0
0.00
16.0K
82.06K
-82K
-$82K
9-12 Months
904.9K
3.29M
498.3K
7.04M
-3.7M
-$3.75M
Top Buyers
Zindrick Thomas
Officer: President And Ceo
$1.74M
Cappello Joseph
Officer: Chief Technical Officer
$519K
Yu Yong
Officer: Svp, Clinical Development
$490K
Smalling Ralph
Officer: Head Of Regulatory
$127K
Tyree James L
Director
$104K
Top Sellers
Zindrick Thomas
Officer: President And Ceo
$5.68M
Yu Yong
Officer: Chief Scientific Officer
$1.27M
Thomas John
Director
$109K
Cappello Joseph
Officer: Chief Technical Officer
$88K
Smalling Ralph
Officer: Head Of Regulatory
$61K
Insider Activity Analysis
Net Insider Sentiment
Negative insider sentiment with $3.91M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
GNLX has not reported any dividend yield values in the available annual periods.
gnlx Dividend History
Learning Layer
Related Guides
Build conviction on GNLX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.